March 4, 2013 Issue | Chemical & Engineering News
 
 
 
Copyright © 2013 American Chemical Society
 

March 4, 2013 Issue

Volume 91, Issue 9
09109-cover1-SaltigoFrankfurtcxd
March 4, 2013 Issue, Vol. 91 | Iss. 9
Biotech firms rely on contract manufacturers for help and guidance on the road to market for new molecules
By Business Department
(p.15)
Features
Science & Technology
Chemists debate the best way to use reaction data to compare catalyst efficiencies (pp. 46-47)
Science & Technology
A potpourri of analytical techniques reveals purported Aztec sculptures are not bona fide (pp. 48-49)
Back Issues
 
Helping Tie Up A Peptide Drug’s Loose Ends
Case Study #1: Ironwood works with peptide makers and others to turn its cross-linked molecule into a drug
(pp. 16-17)
Long-Term Partners
Case Study #2: A decadelong relationship is poised to yield a second polymeric drug
(pp. 18-19)
An Orphan Gets Help
Case Study #3: A race by partners turns an unsuccessful cholesterol drug into a treatment for a rare disorder
(pp. 20-21)
 

News of the Week

Cool Way To Make Hydrogen From Methanol

Fuel Chemistry: Soluble ruthenium catalyst could drop operating temperatures of fuel cells
(p.9)

China Steps Up Toxin Controls

Environment: New action plan acknowledges the presence of cancer clusters
(p.10)

Federal Open-Access Mandate

Publishing: White House directs agencies to provide free access to results of taxpayer-funded research
(p.10)

Bayer And BASF Post Record Sales In 2012

Growth: But net earnings dip at the German chemical giants
(p.11)

River Blindness Marker Found In Patients

Diagnostics: Discovery of parasite-derived metabolite could aid effort to wipe out tropical disease
(p.11)

Toward Silicon Metathesis

Organometallics: Chemists achieve key steps in quest for a silicon version of classic synthesis
(p.12)

White House Aims At Trade Secret Theft

Intellectual Property: Administration’s new strategy has chemical industry support
(p.12)

Dual-Use Research Policies Issued

Biosecurity: Research on avian flu viruses and other pathogens to receive higher level of scrutiny
(p.13)

Royalty Pharma Targets Elan

Buy Proposal: Drug firm scoffs at offer, plans to reinvest coming windfall
(p.13)
 

Departments

09109-cover3-Saltigocxd

Business

Case Study #2: A decadelong relationship is poised to yield a second polymeric drug
(pp. 18-19)
Patent losses on many top-selling drugs caused declines in both sales and earnings
(pp. 34-37)
Case Study #1: Ironwood works with peptide makers and others to turn its cross-linked molecule into a drug
(pp. 16-17)
Case Study #3: A race by partners turns an unsuccessful cholesterol drug into a treatment for a rare disorder
(pp. 20-21)
Fourth-quarter chemical earnings increase as the industry learns to boost profit margins even as sales stagnate
(pp. 30-33)
Biotech firms rely on contract manufacturers for help and guidance on the road to market for new molecules
(p.15)
Money and accomplished scientists boost efforts to build world-class pharmaceutical institutes
(pp. 24-28)

Government & Policy

Science advisers to suggest improvements for work on computational toxicology, cost estimates of regulations
(p.40)
Chemists add to AAAS coalition on intersection of science and human rights
(pp. 41-42)
Some 30 lawmakers come together to advocate for science funding, raise awareness about the role of basic research in economic growth
(p.43)

Books

Pesticide introduced in the 1940s has played a significant role in U.S. history
(pp. 54-55)

Education

Community lauds ACS report on improving graduate education in chemistry but doubts the feasibility of many recommendations
(pp. 51-53)